Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140050 | 0.90 | USP30 (0.47) | MCHR1KCNH2USP30CASP3DRD3 | |
| SCHEMBL4128188 | 0.83 | KCNH2 (0.39) | KCNH2DRD2DRD3 | |
| SCHEMBL4141846 | 0.81 | DRD2 (0.35) | MCHR1KCNH2USP30DRD2DRD3 | |
| SCHEMBL4136050 | 0.79 | CASP3 (0.39) | KCNH2CASP3DRD2DRD3 | |
| SCHEMBL4141749 | 0.78 | MLNR (0.37) | DRD2DRD3 | |
| SCHEMBL4130700 | 0.78 | ALDH1A1 (0.39) | DRD2DRD3 | |
| SCHEMBL4128738 | 0.77 | USP30 (0.36) | KCNH2USP30DRD2DRD3 | |
| SCHEMBL4141105 | 0.74 | CCNT1 (0.46) | MCHR1KCNH2CCNT1CDK9 | |
| SCHEMBL4136323 | 0.74 | IDH1 (0.39) | MCHR1KCNH2USP30CCNT1CDK9 | |
| SCHEMBL4130503 | 0.74 | KCNH2 (0.35) | KCNH2DRD2DRD3PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | MCHR1 287/4885KCNH2 657/4885USP30 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.